Core Insights - Rapid Micro Biosystems, Inc. announced preliminary unaudited revenue for Q4 and full year 2024, indicating significant growth in both periods [2][4][9] Q4 2024 Revenue - The company expects record revenue of approximately 4.2 million, reflecting a growth of approximately 27% year-over-year [9] Full Year 2024 Revenue - Full year 2024 revenue is anticipated to be approximately 15.5 million, showing a growth of around 14% year-over-year [9] System Placement and Validation - In Q4 2024, the company placed six new Growth Direct systems and completed validation for four customer systems, bringing the total to over 160 cumulative systems placed and over 135 validated globally [2][4] - For the entire year of 2024, the company placed 21 new systems and validated 16 customer systems [4] Gross Margin Expectations - The company anticipates a sequential improvement in gross margin for Q4 2024 compared to Q3 2024 [3] Collaboration with Lonza - Rapid Micro Biosystems announced a collaboration with Lonza to integrate the Growth Direct system with Lonza's MODA-EM module, creating a fully automated end-to-end environmental monitoring QC solution [6][9] - This solution is being deployed across Lonza's global cell and gene therapy manufacturing network [6] Upcoming Events - The company is scheduled to present at the 43rd Annual J.P. Morgan Healthcare Conference on January 16, 2024, with a live webcast available for investors [7]
Rapid Micro Biosystems Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Revenue